Table 3 Comparison of demographic data between survivors and non-survivors of PM/DM-ILD patients (excerption^a)

8/14 (57.1%)

75/102 (73.5%)

0.22

PM 1, DM 8, CADM 5

PM 21, DM 43, CADM 38

0.41

60.1 ± 9.6^b

55.5 ± 15.4^b

0.14

Baseline data

KL-6 (U/ml)

935 (809–1230)^c

612 (431–1023)^c

0.016*

Lymphocyte (/μl)

714 (398–909)^c

1,013 (730–1425)^c

0.002**

Albumin (g/dl)

3.03 ± 0.54^b

3.46 ± 0.55^b

0.014*

PaCO₂ (mmHg)

32.6 (31.2–36.0)^c

37.8 (35.3–40.7)^c

0.005**

HRCT

Zone A

2.0 (1.0–2.0)^c

1.0 (0–1.0)^c

<0.001**

Zone B

2.0 (1.0–2.8)^c

1.0 (0–1.0)^c

0.001**

Zone C

2.0 (1.0–3.8)^c

1.0 (1.0–2.0)^c

0.069

Zone D

4.0 (3.0–4.8)^c

3.0 (2.0–4.0)^c

0.021*

Zone total

10.0 (6.5–13.5)^c

6.0 (4.0–8.3)^c

0.004**

Treatment (n (%))

Initial PSL dose (mg/kg/day)

0.96 ± 0.24^b

0.80 ± 0.31^b

0.061

mPSL pulse (n (%))

14/14 (100%)

63/102 (61.8%)

0.002**

IVCY (n (%))

11/14 (78.6%)

37/102 (36.3%)

0.003**

Calcineurin inhibitor

13/14 (92.9%)

68/101 (67.3%)

0.062

Combination therapy^d

10/14 (71.4%)

30/102 (29.4%)

0.005**

Outcome (n (%))

Serious infection

11/14 (78.6%)

27/102 (26.5%)

<0.001**